HZ-G206 / Hangzhou HeZheng Pharma - LARVOL DELTA

Characterization of HZ-G206: A potent and oral small molecule PD-L1 inhibitor (SITC 2022) - "HZ-G206 shows stronger PD-L1 internalization and degradation potency than clinical stage compounds INCB86550 and INCB99318 in hPD-L1-MC38 cell line and IFN-g stimulated human PBMC with IC90 values of 18.1nM and 105.6nM respectively...In in-vivo anti-tumor evaluation, oral administration of HZ-G206 BID can significantly suppress the growth of tumor in a dose dependent manner, the TGI of middle dose group is comparable to Atezolizumab...The compound is identified with potent in-vitro activity which translates to anti-tumor efficacy in pre-clinical animal study. In conclusion, HZ-G206 is an excellent drug candidate for further clinical development."

Oncology • IFNG